Study on Single-cell Regulons Atlas of Pancreatic Ductal Adenocarcinoma

Completed

• Conditions: Pancreatic Ductal Adenocarcinoma (PDAC); Molecular Prognostic Model; Regulons

• Registration Number: NCT06720454
• Lead Sponsor: Tiejun Ying

Brief Summary

The first purpose of this study is to reveal the gene regulatory network of pancreatic cancer by analyzing single-cell transcriptome sequencing data and to draw a pancreatic cancer regulator map. In addition, bulk transcriptome sequencing data are combined to construct and verify the genetic prognostic model of pancreatic cancer regulators, providing clinical tools for accurate prognostic stratification and personalized treatment of pancreatic cancer patients. The second purpose of this study is to explore the molecular mechanism by which the key oncogene in the gene prognostic model promotes pancreatic cancer advance. New ideas and scientific basis are provided for finding potential molecular targets for the treatment of pancreatic cancer. Thus, the investigators included a Tissue Microarray (TMA)-based cohort of 68 PDAC patient tissue samples. TMA was obtained from OUTDO BIOTECH (Shanghai, China). The study was approved by the institutional review board, and ethics document number is YB M-05-01.

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-02
• Primary Completion: 2020-02-25
• Study Completion: 2024-04-21
• Status Verified: 2024-12
• Study First Submitted: 2024-12-01
• Study First Submitted QC: 2024-12-05
• Last Update Submitted: 2024-12-05
• Study First Posted: 2024-12-06
• Last Update Posted: 2024-12-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

• Pancreatic ductal adenocarcinoma
• With post-operative paraffin specimens

Exclusion Criteria

• Other types of pancreatic cancer other than pancreatic ductal adenocarcinoma
• Without post-operative paraffin specimens or less than 20% of the paraffin sections contain cancerous tissue

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intensity of immunofluorescence staining	From January 2019 to January 2024	In this study, 68 pancreatic ductal adenocarcinoma tissues were used to detect the gene expression by multiple immunofluorescence staining

Trial Locations

Locations (1)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; 🇨🇳 Wuhan, Hubei, China